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http://dx.doi.org/10.1016/j.asjsur.20Summary Objective: To examine the expression of Mullerian inhibiting substance (MIS) in
papillary thyroid cancer.
Materials and methods: The MIS expression was examined by studying the immunohistochem-
istry in deparafinized sections prepared from tissue blocks of patients who were diagnosed
with papillary thyroid cancer, as given in the pathology archive records (n Z 23).
Results: In all the cases studied, 50% (n Z 10) showed strong staining and 50% showed
moderate staining. The percentage of staining was found to be 94.2  3.1% in strongly stained
cases and 92.2  2.1% in moderately stained cases. Normal thyroid tissues neighboring the
tumor did not display any staining.
Conclusion: The MIS expression can be used as a significant tool in differential diagnosis of
papillary thyroid cancer and also to shed light on its etiopathogenesis.
Copyright ª 2012, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.of General Surgery, Fırat University, Medical School, Elazig, Turkey.
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The Mullerian inhibiting substance (MIS) is a member of the
transforming growth factor-beta (TGF-b) protein family,
and it is responsible for the regression of the Mullerian
channel in the development of the male embryo.1 The
regulation of the MIS gene expression demonstrates sexual
dimorphism. This hormone, which is considerably high in
neonatal and prepubertal periods in males and immeasur-
ably low in females, reaches equal levels after puberty in
both sexes and drops down to immeasurable levels once
again after menopause in females.2
For many years, the MIS has been thought to have
a limited function in the determination of sex in the
intrauterine period, and only recently, it was found that the
MIS plays significant roles in the testicular maturation in
males and the regulation of follicular growth in females and
that both MIS and its receptors were present in many types
of cancer, most notably ovarian cancer.3,4
The recombinant MIS was shown to cause a strong
blockage of the epidermal growth factor receptor (EGFR) in
complex interactions at the molecular level.5 In a recent
study, it was demonstrated that the EGFR, in turn, contrib-
uted substantially to rearranged during transfection (RET)
kinase activation, a hallmark in papillary thyroid cancer, as
well as many others.6 Despite the established relationship
between EGFR and thyroid cancer, it is not known how the
levels of MIS, whose role is currently under research, are
affected in thyroid cancer.
In this preliminary study, we examine how the MIS levels
are affected in papillary thyroid cancer.
2. Materials and methods
The tissues used in this study were procured from the
archives of the Pathology Department of Fırat University.
Twenty samples from the cases diagnosed as papillary
thyroid cancer in the archive records were randomly
chosen, and their preparations stained with hematoxylin
and eosin were re-examined to reconfirm the diagnosis.
Additionally, sociodemographic characteristics of the cases
were retrieved from the records in their files.
2.1. Tissue preparation and immunohistochemistry
The method developed by Meyts and colleagues was
employed to determine MIS expression in papillary thyroid
cancer using the immunohistochemical method.7 In short,
cross-sections of 4 mm were taken from fixed tissues buried
in paraffin with minor modifications and placed on poly-L-
lysine coated slides using avidin-biotin-peroxidase complex
(ABC) technique (Lab Vision Corporation, USA). All cross-
sections were deparaffinized using routine techniques.
Following deparaffinization, the sections were dehydrated
by passing through three different absolute alcohols and
three different 96% alcohol solutions within 20 minutes.
Subsequently, the tissue sections were treated in the
microwave oven at 1000 W and 400 W for 5 minutes with 5%
urea buffer. The cross-sections were kept at room
temperature for 15 minutes and then incubated in meth-
anol with 2% H2O2 to eliminate endogenous peroxidaseactivity. All the sections were coated with diluted goat
serum to avoid the binding of nonspecific antibodies. The
incubation with a primary antibody was carried out over-
night at 4C.
The antibody was a monoclonal mouse antihuman AMH
(Mab 10.6) from AbD Serotec, cat # MAC2246. The incubation
with the second “link” antibody (biotinylated goat anti-
mouse IgG, Zymed Laboratories, Inc., San Francisco, CA) and
the color development (streptavidineperoxidase complex,
followed by acethylcarbazol and hydrogen peroxide (H2O2))
were performed at room temperature according to manu-
facturer’s instructions. The placental tissue was used as the
negative control. Staining in the range between orange and
light brown was accepted as a positive reaction.
The preparations obtained as such were examined under
a light microscope by two experienced pathologists and
scored according to the severity of staining. Accordingly:
0Z no staining, 1Z mild staining, 2Z moderate staining,
and 3Z strong staining. Furthermore, the staining areas of
all preparations were determined in percentages.
2.2. Statistical analysis
The statistical evaluation was based on the severity and
percentage of staining. The data were expressed as
mean  standard deviation. One-way Analysis of Variance
(ANOVA) was used to compare groups, and Tukey’s tests
were used for post-hoc analysis. Values of p < 0.05 were
considered statistically significant.
3. Results
In this study, 35% of the cases were male and 65% were
female. The mean age was 53  2 years for males and
45  3 years for females. Of all the cases, 50% (n Z 10)
showed strong staining and 50% (nZ 10) showed moderate
staining (Fig. 1). The mean staining surface was found to be
94.2  3.1% in strongly stained cases and 92.2  2.1% in
moderately stained cases. No significant difference was
established between the staining percentages (p > 0.05).
There was no staining in normal thyroid tissues neighboring
the tumor. One metastatic lymph node preparation showed
mild staining, while the other showed no staining. Placental
tissues that were used as controls did not display staining
either. There was no significant difference between males
and females in terms of staining severity and percentage.
The staining levels and percentages of the preparations are
presented in Table 1.
4. Discussion
In our study, the MIS expression in papillary thyroid cancer
was found to be at a high rate and strongmost of the time. To
the best of our knowledge, no study on the presence of MIS in
either normal thyroid tissue or thyroid cancers has been
mentioned in the literature. The MIS expression in papillary
thyroid cancer has been shown for the first time in this study.
Our literature review has revealed that just as MIS
inhibits Mullerian structures in the embryonic period, it
continues to exert this inhibiting effect in the postnatal
Figure 1 Severity scores of Mullerian inhibiting substance
staining under a light microscope in papillary thyroid
carcinomas.
Table 1 Severity and percentage of MIS staining under
a light microscope in papillary thyroid carcinomas.
Biopsy no. Severity of staining
(0: no staining, 1:
mild staining, 2:
moderate staining,
3: strong staining)
Percentage
of staining
1 3 80%
2 2 90%
3 2 100%
4 2 90%
5 2 80%
6 3 80%
7 3 100%
8 3 90%
9 2 80%
10 3 90%
11 3 100%
12 2 100%
13 3 90%
14 3 80%
15 3 90%
16 2 80%
17 2 70%
18 2 80%
19 3 100%
20 2 80%
21 e Lymph
node metastasis
1 30%
22 e Lymph
node metastasis
0 0%
23 e Placenta 0 0%
MIS Z Mullerian inhibiting substance.
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cancers, and most notably in the ovarian cancer, through
different mechanisms.8e11
The MIS binds to Type I and II receptors in the cell
membrane. The bioactive MIS forms a heteromeric complex
with transmembrane serine/threonine kinases. The extra-
cellular cysteine-rich domain of the Type II receptor ligand
ensures specificity. FKBP-12-bound Type I receptors
strengthen Type II and maintain signal transmission.2
The purified recombinant human MIS was shown to inhibit
growth in ovarian cells via a receptor-mediated mechanism
both in vivo and in vitro. Similarly, the MIS was demon-
strated to inhibit growth in endometrial, cervical, and
breast cancers, where the MIS receptors are found through
receptor-mediated mechanisms.8e17 On the basis of these
data, it can be speculated that MIS is expressed in response
to the proliferative effect of the EGFR, which is known to
have a strong proliferative effect in thyroid cancer.
However, thus far, there is no clarity regarding those
growth factors inhibited by MIS in papillary thyroid cancers.
Although the oncogenic potential of rearranged in
transformation/papillary thyroid carcinomas (RET/PTC),
the most commonly established genetic modification in
papillary thyroid cancer, is in a close relationship with
intrinsic tyrosine kinase activity, the substrates of thisenzyme are not clear. Kim et al. reported in their study that
serine/threonine kinases were also used as targets of RET/
PTC in growth-factor signaling pathways and that the con-
cerned pathway might be among the mechanisms in thyroid
carcinogenesis.18 An overall evaluation of this information
suggests that the elevated expression of MIS in papillary
thyroid cancer may be through the serine/threonine
kinases pathway.
However, when the fact that a high number of studies are
needed to clarify the mechanism of MIS expression is set
aside, our finding in the immunohistochemical differentia-
tion of papillary thyroid cancer is a new marker. There was
little or no immunohistochemical staining outside the normal
thyroid cancer sites in our study,which suggests that it canbe
used as a new marker in differential diagnosis.
We have presented an excellent finding for the diag-
nosis of papillary cancer. We demonstrated MIS expression
in papillary cancer tissues only by employing the immu-
nohistochemical method that was developed by Meyts and
colleagues.7 We did not use Western blotting or enzyme-
linked immunosorbent assay (ELISA), but we believe that
MIS Expression in thyroid cancer 129further prospective studies need to be conducted on MIS.
We had conducted our retrospective study only on the
pathological blocks of tissues from patients diagnosed
with papillary cancer. We had also observed that there
was no MIS expression in the sections of normal thyroid
tissue. Therefore, we did not include a control group in
our study.
In conclusion, due to the fact that MIS has been started
to be studied only recently, there is insufficient information
on the interaction of this hormone with other systems, the
tissues in which it has receptors, and its relation with
cancers, except for a limited number of gynecologic
cancers. Further studies on MIS are needed to interpret the
findings obtained in our study.
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